

May 11, 2021

Positive Outlook Despite Weak Start

Low Asset Yields Remain a Pain Point for Topline Performance

First Bank of Nigeria Holding Plc (FBNH) kick started the year on a weak footing. Gross earnings recorded its worst performance (-14.49% YoY to NGN136.55bn) in five years, driven by a sharp decline (25.31% YoY) in interest income. The fall in interest income was off the back of significantly lower asset yield (6.80% in Q1:2021 vs 10.90% in Q1:2020). We note specifically that interest income on investment securities fell by 61.83% YoY while interest on loans decreased by 6.41% YoY. In contrast, non-interest income maintained its uptrend due to higher electronic transaction volumes (e-banking fees grew by 30.74% YoY), and trading gains on investment securities (+32.32% YoY). For the rest of the year, we expect interest income to reverse its downtrend in subsequent quarters due to the following factors: an increase in the stock of investment securities; yield reversal in Q2:2021; and an observed shift in the maturity profile of investment securities in favor of longer term securities, which earn higher interest. We also expect the growth momentum in non-interest income to be sustained throughout 2021 owing to higher transaction volumes, especially as Management replicates its agent banking strategy in other African subsidiaries.

Elevated Impairment Charges and Lower Operating Income Drag Profitability

Cost of funds declined further to 1.60% from 3.30% in Q1:2020 and continues to benefit from the adjustments in the CASA mix (67.35% vs 60.18% in Q1:2020) towards low-cost funding. Nevertheless, Net Interest Margin (NIM) contracted by c.170bps YoY to 4.60% due to the weightier impact of lower asset yield as highlighted earlier. Impairment charges on the other hand maintained an uptrend as they increased significantly by 35.74% YoY to NGN13.18bn. Meanwhile, although growth in operating costs was modest (2.41% YoY), we draw attention to the substantial increase in regulatory costs (+36.89% YoY). Thus, the combined effect of lower operating income (-4.16% YoY) and higher impairment charges, led to an uptick in the lender's Cost-to-Income Ratio (CIR) by 446.56bps YoY to 69.57%. Consequently, Profit After Tax fell by 39.22% YoY to NGN15.62bn. While we expect topline to improve in subsequent quarters, we are cautious about the impact of higher regulatory costs as well as heightened inflationary pressures on the group's operating expenses. We are also keeping a close eye on impairment charges which we expect to moderate as the year progresses. Thus, we revise our 2021FY Profit After Tax downward to NGN97.84bn, representing +9.04% YoY growth.


Asset Quality Improvement on Track

The consistent decline in the Non-Performing Loan (NPL) ratio of the Tier-1 lender is encouraging as it points to a continuous improvement in the group's asset quality. In Q1:2021, the NPL ratio declined to 7.90% from 9.20% in Q1:2020. (Recall that as at 2020FY, the group's NPL ratio came in at 8.39% vs. 10.20% in 2019FY). We however note that while actual NPLs have declined (-3.60% YoY), increase in gross loans (+12.27% YoY) also contributed to the lower NPL ratio. Barring any adverse economic event, we expect to see the group's NPL ratio subside below 7.00% in 2021FY. Other prudential ratios, particularly capital adequacy (at 16.60%) are well within regulatory guidance and are expected to remain so over the near-to-medium term.

Recommendation

While we are optimistic about FBNH's performance in subsequent quarters of the year, full year outlook is now constrained by the group's weaker than expected Q1:2021 performance. Therefore, we revise our 2021FY expected EPS downwards to NGN2.59 (from NGN2.85) while maintaining a target P/E of 3.22x, resulting in a new 2021FY target price of NGN8.34. This suggests an upside of +13.47%. Thus, we recommend a BUY on the ticker.

| Company | FBNH |
|-----------------------------|------------|
| | |
| Valuation | |
| Trailing EPS | 2.22 |
| BVPS | 21.31 |
| P/E | 3.29x |
| P/BV | 0.34x |
| Target PE | 3.22 |
| Dec-2021 Exp. EPS | 2.59 |
| Dec 2021 Target price | 8.34 |
| Current Price | 7.30 |
| Up/Downside Potential | +13.47% |
| Ratings | BUY |
| Key metrics | |
| ROE | 10.41% |
| ROA | 1.03% |
| Net margin | 11.44% |
| Asset Turnover | 0.07 |
| Leverage | 10.25x |
| Share/Share Price | |
| Statistics | |
| Yr Hi | 7.85 |
| Yr Lo | 6.90 |
| YTD return | 2.80% |
| Beta | 1.34 |
| Adjusted Beta | 1.23 |
| 52-wk average volume | 31,499,362 |
| Shares outstanding | 35.90 |
| Market cap [NGN] | 262.04 |
| Financial year end | December |
| Most Recent Period (MRP) | Q1:2021 |





May 11, 2021

Chart 1: Sensitivity Analysis

| Sensitivity Analysis of Dec-2021 Target Price to key model inputs | | | | Min | 7.77 | | | |
|---|-------|------|------|------|------|------|------|--|
| | | EPS | | | | Max | 8.93 | |
| | | 2.49 | 2.54 | 2.59 | 2.64 | 2.69 | | |
| | 3.12x | 7.77 | 7.92 | 8.08 | 8.24 | 8.39 | | |
| | 3.17x | 7.89 | 8.05 | 8.21 | 8.37 | 8.53 | | |
| Target PE | 3.22x | 8.02 | 8.18 | 8.34 | 8.50 | 8.66 | | |
| | 3.27x | 8.14 | 8.31 | 8.47 | 8.63 | 8.80 | | |
| | 3.32x | 8.27 | 8.43 | 8.60 | 8.76 | 8.93 | | |

| Financial Highlights (NGN billion) FBN HOLDINGS PLC Q1:2 | 2021 | | |
|--|----------|----------|------------|
| Profit & Loss Account | Q1:2021 | Q1:2020 | y/y Growth |
| Gross Earnings | 136.55 | 159.68 | -14.49% |
| Interest Income | 78.36 | 104.91 | -25.31% |
| Interest Expense | 25.56 | 44.65 | -42.75% |
| Net Impairment Charges | 13.18 | 9.71 | 35.74% |
| Net Interest income after impairment charges | 39.62 | 50.55 | -21.62% |
| Non-Interest Income | 58.22 | 54.78 | 6.28% |
| Operating Income | 105.41 | 109.99 | -4.16% |
| OPEX | 73.33 | 71.61 | 2.41% |
| PBT | 18.91 | 28.68 | -34.08% |
| PAT | 15.62 | 25.70 | -39.22% |
| Balance Sheet | Q1:2021 | 2020FY | |
| Cash and Balances with Central Banks | 1,684.61 | 1,631.73 | 3.24% |
| Loans and Advances to customers | 2,299.58 | 2,217.27 | 3.71% |
| Investment Securities | 1,785.45 | 1,549.29 | 15.24% |
| Property and Equipment | 114.29 | 114.03 | 0.23% |
| Other Assets | 1,951.87 | 2,176.71 | -10.33% |
| Total Assets | 7,835.80 | 7,689.03 | 1.91% |
| Deposits from customers | 5,096.50 | 4,894.72 | 4.12% |
| Financial Liabilities | 1,382.76 | 1,418.70 | -2.53% |
| Other Liabilities | 591.70 | 610.44 | -3.07% |
| Total Liabilities | 7,070.96 | 6,923.86 | 2.12% |
| Shareholders' fund | 764.84 | 765.17 | -0.04% |



May 11, 2021

Contact Information

Brokerage and Retail Services

topeoludimu@meristemng.com (+234 905 569 0627) olatunjifaniyi@meristemng.com (+234 803 446 3118) contact@meristemng.com

Investment Banking/Corporate Finance

rasakisalawu@meristemng.com (+234 806 022 9889) seunlijofi@meristemng.com (+234 808 536 5766)

Wealth Management

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522)

crmwealth@meristemng.com

Tel: +234 01 738 9948

Registrars

muboolasoko@meristemregistrars.com (+234 803 324 7996) martinaosague@meristemregistrars.com (+234 802 303 1783) www.meristemregistrars.com

Tel: +23401-280 9250

Trust Services

damilolahassan@meristemng.com (+234 803 613 9123) crmwealth@meristemng.com

Group Business Development

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaogalue@meristemng.com (+234 802 3942967) info@meristemng.com

Client Services

adefemitaiwo@meristemng.com (+234 803 694 3034) blessingogwuche@meristemng.com (+234 706 896 5173) car@meristemng.com

Investment Research

www.meristemng.com

ahmedjinad@meristemng.com (+234 809 183 9487) research@meristemng.com

Meristem Research can also be FBNHed on the following platforms:

Meristem Research portal: meristem.com.ng/rhub

Bloomberg: MERI <GO>

Corporate websites:

Capital IQ:www.capitaliq.comReuters:www.thomsonreuters.comISI Emerging Markets:www.securities.com/ch.html?pc=NGFactSet:www.factset.com

www.meristemwealth.com

NSE: FBNH I Bloomberg: FBNH:NL I Reuters: FBNH.LG

www.meristemregistrars.com



May 11, 2021

Analyst's Certification and Disclaimer

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

BUY: Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between -10 percent and 10 percent from the current market price.

SELL: Target Price of the stock is more than **10 percent** below the current market price.



May 11, 2021

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.

Movements in Price Target

Company Name: FBN HOLDINGS Plc.

| Date | Price (N) | Previous Target Price(N) | New Target Price (N) | Previous Recommendation | New Recommendation |
|-------------|-----------|-----------------------------|-------------------------|----------------------------|-----------------------|
| 19-Apr-2021 | 7.60 | 8.69 | 9.02 | BUY | BUY |
| 11-May-2021 | 7.35 | 9.02 | 8.34 | BUY | BUY |

Company disclosures

Meristem or the analyst(s) responsible for the coverage may have financial or beneficial interest in securities or related investments discussed in this report, which could, unintentionally, affect the objectivity of this report. Material interests, which Meristem or the analyst(s) have with companies or in securities discussed in this report, are disclosed below:

| Company | Disclosure |
|------------------------------------|------------|
| First Bank of Nigeria Holdings Plc | |
| | |

- a. The analyst(s) hold(s) personal positions (directly or indirectly) in a class of the common equity securities of the company.
- b. The analyst responsible for this report, as indicated on the front page, is a board member, officer or director of the company
- c. Meristem beneficially owns 1% or more of the equity securities of the company
- d. Meristem has been the lead manager or co-lead manager of any publicly disclosed offer of securities of the company over the past 12 months.
- e. Meristem beneficially holds a major interest in the debt of the company
- f. Meristem has received compensation for investment banking activities from the company within the last 12 months
- g. Meristem intends to seek, or anticipates receipt of compensation for investment banking services from the company in the next 3 months
- h. The content of this research report has been communicated with the company, following which this research has been materially amended before its distribution
- i. The company is a client of the stock broking division of the Meristem group.
- j. The company is a client of the investment banking division of the Meristem group.
- Meristem is the registrar to the company.
- I. The company owns more than 5% of the issued share capital of Meristem
- m. Meristem has other financial or other material interest in the company.



May 11, 2021

Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Mersitem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, the company through its subsidiaries carries out stock broking, wealth management, trustees and registrars businesses which are regulated by the SEC and ICMR.

Copyright 2021 Meristem Securities Limited. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Meristem Securities Limited.